Press Archive
Press Releases
2020-09-02
Umecrine Cognition to present clinical Phase 2a results at AASLD International Liver Meeting
2020-05-08
Umecrine Cognition announces positive additional endpoint data from a phase 2a study with golexanolone in hepatic encephalopathy
2020-04-03
Umecrine Cognition announces top-line results from its phase 2a study with golexanolone in hepatic encephalopathy
2019-12-20
Umecrine Cognition announces a Notice of Allowance from USPTO for a patent protecting a pharmaceutical formulation of its proprietary lead compound golexanolone
2019-12-13
Umecrine Cognition announces completion of enrollment in clinical Phase 2a study with golexanolone in patients with liver cirrhosis and hepatic encephalopathy
2019-02-18
Umecrine Cognition announces first patient included in part D in clinical Phase 2a study with GR3027 in patients with liver cirrhosis and hepatic encephalopathy
2019-01-29
Umecrine Cognition announces results from a Phase 2a study of GR3027 in patients with idiopathic hypersomnia
2018-12-12
Umecrine Cognition granted a European patent protecting its lead candidate drug GR3027
2018-12-03
Umecrine Cognition appoints Dr. Eva Arlander as Chief Development Officer
2018-03-02
Umecrine Cognition announces on-line publication of Clinical trial results perteining to GR3027 safety, pharmacokinetics and CNS target engagement
2017-11-20
Umecrine Cognition announces first patient included in clinical Phase 2a study in patients with sleep disorder
2017-10-04
Umecrine Cognition raises SEK 20 million to treat unmet needs in sleep disorder
2017-09-13
Umecrine Cognition announces positive data from its Phase 1b study of GR3027 - a potential new treatment of hepatic encephalopathy
2017-09-05
Umecrine Cognition appoints Dr. Thomas P. Blackburn to its board of directors
2017-04-21
Umecrine Cognition to present at the EASL International Liver Congress 2017
2017-03-17
Umecrine Cognition announces first patient included in Clinical Phase 1b/2a study with GR3027, a novel drug candidate for Hepatic Encephalopathy
2016-11-22
Umecrine Cognition raises SEK 45 million to advance GR3027, a novel drug candidate for hepatic encephalopathy
2016-11-03
Positive Phase 1 top line data with GR3027 demonstrate safety, tolerability, and CNS target engagement
2016-07-05
Umecrine Cognition appoints Dr. Bruce Scharschmidt to its board of directors.
2016-03-10
Umecrine Cognition raises new funds to support clinical development of novel drug candidate GR3027 for Hepatic Encephalopathy - Phase I clinical trial initiated.
2015-12-09
Umecrine Cognition announces grant of a US patent protecting its lead candidate drug GR3027.
2015-08-19
GR3027 normalizes the neurolological symptoms in two preclinical models of Hepatic Encephalopathy.
2013-10-23
Umecrine Cognition signs partnering agreement with CleveXel Pharma.
2012-02-01
Magnus Doverskog appointed as new CEO for Umecrine Cognition.
Images and Logos
![]() Magnus DoverskogJPEG, RGB 165 K | ![]() Logo - High QualityJPEG, 300 PPI, CMYK 503 K |
---|---|
![]() Logo - Low QualityJPEG, 72 PPI, RGB 71 K |